Therapeutic Indications

Apixaban is indicated for:

Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)

Irrespective of gender only Adults (18 years old or older)

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 5-20 mg in 2 divided doses daily

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF)

Irrespective of gender only Adults (18 years old or older)

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 5-10 mg in 2 divided doses daily

Prevention of venous thromboembolic events in total hip replacement surgery or total knee replacement surgery

Irrespective of gender only Adults (18 years old or older)

Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 5 mg in 2 divided doses daily

Contraindications

Active ingredient Apixaban is contraindicated in the following cases:

Active clinically significant bleeding

No gender/age discrimination

Lesion or condition, if considered a significant risk factor for major bleeding

No gender/age discrimination

Lesion or condition if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.

Severe hepatic impairment

No gender/age discrimination

Eliquis is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk. It is not recommended in patients with severe hepatic impairment.

Anticoagulants

No gender/age discrimination

Concomitant treatment with any other anticoagulant agent e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter.